Development of new treatment strategy targeting mitotic kinases in hematological malignancies
| Project/Area Number |
20591131
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Kochi University |
|---|
Principal Investigator |
IKEZOE Takayuki Kochi University, 教育研究部・医療学系, 講師 (80294833)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 分裂期キナーゼ / 造血器悪性腫瘍 / 急性白血病 / JAK2キナーゼ / apoptosis / 悪性リンパ腫 |
|---|
| Research Abstract |
Polo-like kinase1 (PLK1) belongs to the family of serine/threonine kinases and plays an important role in centrosome maturation, bipolar spindle formation, and cytokinesis during mitosis. We found in this study that PLK1 was aberrantly highly expressed in freshly isolated leukemia cells from individuals with acute myelogenous leukemia (AML, n=50) and acute lymphoblastic leukemia (ALL, n=15) compared to bone marrow mononuclear cells from healthy volunteers (n=13) (AML, p=0.016; ALL, p=0.008), as measured by real-time RT-PCR. Down-regulation of PLK1 by a small interfering RNA (siRNA) in NB4 AML cells inhibited their proliferation. GW843682X is a novel selective PLK1 inhibitor. The compound induced growth inhibition, caused accumulation of cells in the G2/M phase of the cell cycle and mediated apoptosis of human leukemia cells. Taken together, targeting PLK1 may be a promising treatment strategy for individuals with leukemia.
|
Report
(4 results)
Research Products
(37 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] An oncogenic role for CCAAT/enbancer binding protein beta in non-small cell lung cancer. AACR 101st Annual Meeting 20102010
Author(s)
Nils H.Thoennissen, Gabriela B.Iwanski, Jianfei Ji,Takayuki Ikezoe, Kunik Lee, Yoshihiro Adachi,Tamotsu Takeuchi, Mutsuo Furihata, Dorothy J.Park, Adrian F.Gombart, H.P.Koffler.
Place of Presentation
Washington, DC
Related Report
-
-
[Presentation] Recombinant Human Soluble Thrombomodulin Enhances the Anti-Fibrinolytic and Ant Effects of All-Trans Retinoic Acute Promyelocytic Leukemia Cells. 52nd ASH Annual Meeting and Exp2010
Author(s)
Takayuki Ikezoe, Jing Yang, Chie Nishioka, Mayuka Isaka, Naomi Iwabu, Mizu Sakai, Ayuko Taniguchi, Kazuto Togitani, Goichi Honda, Akihito Yokoyama.
Place of Presentation
Orange County Convention Center, Orlando, FL
Related Report
-
-
-
-
-
-
